替加环素
医学
回顾性队列研究
耐受性
内科学
相伴的
重症监护
逻辑回归
前瞻性队列研究
重症监护医学
队列研究
比例危险模型
抗生素
碳青霉烯
感染性休克
儿科
临床终点
急诊医学
临床试验
队列
重症监护室
背景(考古学)
外科
优势比
四分位间距
抗菌剂
作者
Mustafa Gençeli,Talha Üstüntaş,Ozge Metin Akcan,Melda Özdemir,Hatice Kübra Körpe Boğaz,Betül Cığal,Kübranur Erdoğan,Abdullah Akkuş,Abdülkerim Çokbiçer
标识
DOI:10.1080/14787210.2026.2670678
摘要
BACKGROUND: Pediatric data on tigecycline for multidrug-resistant infections caused by gram-negative bacteria remain scarce. We described clinical outcomes and tolerability of tigecycline in critically ill children at a single tertiary center. RESEARCH DESIGN AND METHODS: In this retrospective cohort study, 143 pediatric patients receiving tigecycline (1-1.2 mg/kg or 50 mg twice daily) between January 2018 and September 2023 were analyzed. Most patients (72.0%) required intensive care; 66.4% received combination therapy. Primary outcome was clinical success (infection resolution with marker normalization). Logistic regression and Cox modeling assessed success and mortality predictors; Kaplan-Meier curves compared survival. Paired laboratory data assessed tolerability. RESULTS: (17.5%) predominated; 87% of isolates displayed carbapenem resistance. Clinical success reached 76.9%. Intensive care admission and combination therapy independently predicted failure. Overall infection-related mortality was 28.7%; intensive care admission was the sole independent mortality predictor. Paired laboratory values showed no significant hepatic, pancreatic, or hematological changes; one biliary sludge event was recorded. CONCLUSIONS: Tigecycline, a glycylcycline antimicrobial, was associated with favorable outcomes and acceptable tolerability in children with multidrug-resistant infections. The single-center retrospective design, absence of a control group, and frequent concomitant antibiotic use limit generalizability; prospective trials are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI